There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Jim Cramer, the host of Mad Money, recently took a deep dive into the challenges facing the consumer packaged goods sector, ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.